76 related articles for article (PubMed ID: 19939517)
1. Preparation of synthetic polyoxazoline based carrier and Vibrio cholerae O-specific polysaccharide conjugate vaccine.
Farkas P; Korcová J; Kronek J; Bystrický S
Eur J Med Chem; 2010 Feb; 45(2):795-9. PubMed ID: 19939517
[TBL] [Abstract][Full Text] [Related]
2. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier.
Chernyak A; Kondo S; Wade TK; Meeks MD; Alzari PM; Fournier JM; Taylor RK; Kovác P; Wade WF
J Infect Dis; 2002 Apr; 185(7):950-62. PubMed ID: 11920320
[TBL] [Abstract][Full Text] [Related]
3. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation of T-cell responses with Vibrio cholerae O135 capsular polysaccharide and its protein conjugate, novel cholera vaccine study models.
Paulovičová E; Korcová J; Machová E; Bystrický S
FEMS Immunol Med Microbiol; 2012 Aug; 65(3):422-30. PubMed ID: 22443716
[TBL] [Abstract][Full Text] [Related]
5. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
[TBL] [Abstract][Full Text] [Related]
6. [The use of liposomes for detection of the surface lipopolysaccharide antigen, Vibrio cholerae cells, and antibodies against them].
Skopinskaia SN; Iarkov SP; Khramov EN
Prikl Biokhim Mikrobiol; 2005; 41(2):228-34. PubMed ID: 15859469
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.
Kossaczka Z; Szu SC
Glycoconj J; 2000 Jun; 17(6):425-33. PubMed ID: 11294508
[TBL] [Abstract][Full Text] [Related]
8. [A new vaccine concept: polysaccharide conjugate vaccines].
Moreau M
Ann Pharm Fr; 1999 May; 57(3):223-31. PubMed ID: 10427857
[TBL] [Abstract][Full Text] [Related]
9. Preparation and immunogenicity of conjugate based on hydrazine-treated lipopolysaccharide antigen of Vibrio cholerae O139.
Fleischhackerová A; Farkaš P; Cížová A; Bystrický S
Biosci Biotechnol Biochem; 2014; 78(11):1817-24. PubMed ID: 25070088
[TBL] [Abstract][Full Text] [Related]
10. Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.
Ftacek P; Nelson V; Szu SC
Glycoconj J; 2013 Dec; 30(9):871-80. PubMed ID: 23955520
[TBL] [Abstract][Full Text] [Related]
11. Improved conjugation and purification strategies for the preparation of protein-polysaccharide conjugates.
Suárez N; Massaldi H; Franco Fraguas L; Ferreira F
J Chromatogr A; 2008 Dec; 1213(2):169-75. PubMed ID: 18992885
[TBL] [Abstract][Full Text] [Related]
12. Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies.
Meeks MD; Saksena R; Ma X; Wade TK; Taylor RK; Kovác P; Wade WF
Infect Immun; 2004 Jul; 72(7):4090-101. PubMed ID: 15213154
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a MUC1-glycopeptide-BSA conjugate vaccine bearing the 3'-deoxy-3'-fluoro-Thomsen-Friedenreich antigen.
Hoffmann-Röder A; Johannes M
Chem Commun (Camb); 2011 Sep; 47(35):9903-5. PubMed ID: 21818465
[TBL] [Abstract][Full Text] [Related]
15. O-Antigen Extraction, Purification, and Chemical Conjugation to a Carrier Protein.
Micoli F; Giannelli C; Di Benedetto R
Methods Mol Biol; 2021; 2183():267-304. PubMed ID: 32959249
[TBL] [Abstract][Full Text] [Related]
16. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines.
Stefanetti G; Rondini S; Lanzilao L; Saul A; MacLennan CA; Micoli F
Vaccine; 2014 Oct; 32(46):6122-9. PubMed ID: 25192974
[TBL] [Abstract][Full Text] [Related]
17. Conjugation of LPS-derived oligosaccharides to proteins using oxime chemistry.
Kubler-Kielb J
Methods Mol Biol; 2011; 751():317-27. PubMed ID: 21674340
[TBL] [Abstract][Full Text] [Related]
18. The development of a bivalent vaccine against diarrhoeal disease.
Forrest BD
Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):449-57. PubMed ID: 2464195
[TBL] [Abstract][Full Text] [Related]
19. Exploration of Moraxella catarrhalis outer membrane proteins, CD and UspA, as new carriers for lipooligosaccharide-based conjugates.
Hu WG; Berry J; Chen J; Gu XX
FEMS Immunol Med Microbiol; 2004 Jun; 41(2):109-15. PubMed ID: 15145454
[TBL] [Abstract][Full Text] [Related]
20. Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.
Pan C; Sun P; Liu B; Liang H; Peng Z; Dong Y; Wang D; Liu X; Wang B; Zeng M; Wu J; Zhu L; Wang H
mBio; 2016 Apr; 7(2):e00443-16. PubMed ID: 27118590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
